Zachary Cahn

Zachary Cahn

Auto-generated profile, based on publicly available information

Zachary Cahn

Center for Tobacco Products, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, United States, 1 (888) 463-6332

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

5 April 2018 in Journal of Smoking Cessation
Verified
Journal Article
Closed access
PDF file
ZCZachary Cahn
Zachary Cahn
RHRegine Haardörfer
Regine Haardörfer
MLMichael Lewis
Michael Lewis
YWYanwen Wang
Yanwen Wang
CBCarla J. Berg
Carla J. Berg
Objectives: Examine correlates of initiation of e-cigarette use among smokers and determine the impact of e-cigarette use on cessation among smokers in a national U.S. consumer panel.Methods: This study used the Nielsen Homescan Panel data from 2011 to 2013, augmented with state-specific measures of tobacco control activities, to examine (1) correlates of single and repeat e-cigarette purchasing among panellists currently purchasing cigarettes; and (2) correlates of ‘cessation’. Participating panellists scanned all retail purchases, and Nielsen recorded over 3 million product types. The key explanatory variable for cessation was e-cigarette purchase. Parallel analysis was conducted for conventional nicotine replacement therapy (NRT) purchase. Cessation was defined as no purchases for at least 6 months and no subsequent purchases until the end of 2013. Analysis was conducted in 2015. E-cigarettes tracked by Nielsen during this period were cig-a-like products resembling tobacco cigarettes in appearance.Results: Single e-cigarette purchase was associated with whether the panellist resided in a single person male household and bought a higher volume of cigarettes. Repeat purchase was associated with higher state cigarette taxes, less stringent state public smoke-free policies, lower cigarette prices, and more frequent cigarette purchasing. Cessation was associated with repeat e-cigarette purchasing, repeat NRT purchasing, younger age, lower monthly cigarette volume, less frequent purchasing of cigarettes, less recent cigarette purchase at baseline, and single e-cigarette purchase before baseline.Conclusions: Both individual and policy variables were associated with e-cigarette use. Repeat e-cigarette purchase was associated with cigarette purchase discontinuation, as were various smoking intensity measures.

12 March 2018 in Journal of Public Health Policy
Verified
Journal Article
Closed access
PDF file
ZCZachary Cahn
Zachary Cahn
LELindsay Eckhaus
Lindsay Eckhaus

5 August 2025 in JMIR Preprints
Verified
Preprint
Open access
HSHyungsik Shin
Hyungsik Shin
JHJonathan Hannings
Jonathan Hannings
ZCZachary Cahn
Zachary Cahn
XXXin Xu
Xin Xu
RTRobin Toblin
Robin Toblin
BKBrian King
Brian King
BACKGROUND In 2023, Esco Bars was the second most commonly reported e-cigarette brand used among U.S. middle and high school student e-cigarette users. These products have not been authorized for sale in the United States by the U.S. Food and Drug Administration (FDA). On May 12 and May 25, 2023, FDA issued an import alert and a warning letter, respectively, to the manufacturer requiring them to immediately remove these unauthorized products from the market. On June 22 and July 27, 2023, FDA also issued warning letters to U.S. retailers and distributors, respectively, regarding the illicit sale of these unauthorized products. This study evaluated the impact of these advisory and enforcement actions on retail sales of Esco Bars in the United States. OBJECTIVE We evaluated the impact of these 2023 FDA advisory and enforcement actions on illicit sales of unauthorized Esco Bars to better inform future regulatory decision-making. METHODS This study used a synthetic control method to evaluate the impact of 2023 FDA advisory and enforcement actions on Esco Bars sales based on weekly sales data from NielsenIQ Retail Measurement Service between January 1 and December 30, 2023. Data came from the 48 contiguous states; data were not available for Internet and vape shop sales. First, we standardized the data by transforming weekly sales into Z-scores. Second, we created a synthetic comparison for Esco Bars sales based on sales of other e-cigarettes for which FDA did not take actions during the analytical period. Finally, we calculated the difference in sales between Esco Bars and the comparison group before and after the FDA actions. To assess the robustness of the findings, we used other standardization methods for sensitivity analyses. RESULTS By the last week of 2023, actual Esco Bars weekly sales were 68.5% lower than estimated sales in the comparison group (p=0.019). Over the 5-month period following FDA advisory and enforcement actions, Esco Bars product sales were reduced by approximately 1.7 million equivalized units (p=0.058). These findings were robust across sensitivity analyses. CONCLUSIONS FDA’s advisory and enforcement actions substantially reduced sales of Esco Bars products in the U.S., with a sustained impact noted over a 5 month period. These findings underscore the importance and impact of FDA actions against unauthorized tobacco products as part of a comprehensive regulatory approach.

4 March 2020 in Journal of Smoking Cessation
Verified
Journal Article
Open access
PDF file
ZCZachary Cahn
Zachary Cahn
RHRegine Haardörfer
Regine Haardörfer
MLMichael Lewis
Michael Lewis
YWYanwen Wang
Yanwen Wang
CBCarla J. Berg
Carla J. Berg

12 March 2026 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
HSHyungsik Shin
Hyungsik Shin
JHJonathan Hannings
Jonathan Hannings
ZCZachary Cahn
Zachary Cahn
XXXin Xu
Xin Xu
RTRobin Toblin
Robin Toblin
BKBrian King
Brian King
Background: In 2023, Esco Bars was the second most commonly reported e-cigarette brand used among US middle and high school student e-cigarette users. These products have not been authorized for sale in the United States by the US Food and Drug Administration (FDA). On May 12, 2025, and May 25, 2023, the FDA issued an import alert and a warning letter, respectively, to the manufacturer requiring them to immediately remove these unauthorized products from the market. On June 22, 2023, and July 27, 2023, the FDA also issued warning letters to US retailers and distributors, respectively, regarding the illicit sale of these unauthorized products. This study evaluated the impact of these advisory and enforcement actions on retail sales of Esco Bars in the United States. Objective: We evaluated the impact of these 2023 FDA advisory and enforcement actions on illicit sales of unauthorized Esco Bars to better inform future regulatory decision-making. Methods: This study used a synthetic control method to evaluate the impact of 2023 FDA advisory and enforcement actions on Esco Bars sales based on weekly sales data from the NielsenIQ Retail Measurement Service between January 1, 2023, and December 30, 2023. Data came from the 48 contiguous states and were not available for internet and vape shop sales. First, we standardized the data by transforming the weekly sales into z scores. Second, we created a synthetic comparison for Esco Bars sales based on sales of other e-cigarettes for which the FDA did not take action during the analytical period. Finally, we calculated the difference in sales between Esco Bars and the comparison group before and after the FDA actions. To assess the robustness of the findings, we used other standardization methods for sensitivity analyses. Results: By the last week of 2023, actual Esco Bars’ weekly sales were 68.5% lower than the estimated sales in the comparison group ( P =.02). Over the 5-month period following FDA advisory and enforcement actions, Esco Bars product sales were reduced by approximately 1.7 million equivalized units ( P =.06). These findings were robust across sensitivity analyses. Conclusions: The FDA’s advisory and enforcement actions substantially reduced sales of Esco Bars products in the United States, with a sustained impact noted over a 5-month period. These findings underscore the importance and impact of FDA actions against unauthorized tobacco products as part of a comprehensive regulatory approach.